A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/16061869

Clin. Cancer Res. 2005 Aug 1 11 15 5526-33

Download in:

View as

Triples

General Info

PMID
16061869